The anti‐PD‐1 monotherapy is the first‐line treatment for patients with NSCLC with at least 50% or more of PD‐L1 expression on tumor cells and platinum‐doublet chemotherapy plus anti PD‐1 is the first‐line therapeutic option for nonsquamous‐cell NSCLC. This evidence concerns the gene CD274 and neoplasm.